Nivolumab plus ipilimumab: a potential regimen to rewrite treatment guidelines for ESCC.

ABSTRACT:

SUBMITTER: Luo Y 

PROVIDER: S-EPMC9132968 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature